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Prevalence of non-alcoholic fatty liver disease is in-
creased in patients with psoriasis. However, it is not 
known how liver fibrosis correlates with psoriasis. This 
study investigated the association between psoriasis and 
liver fibrosis compared with participants without pso-
riasis within the population-based Rotterdam Study. 
All participants were screened for liver fibrosis using 
transient elastography. Liver stiffness > 9.5 kPa sug-
gested advanced liver fibrosis. Psoriasis was identified 
using a validated algorithm. A total of 1,535 participants 
were included (mean age ± standard deviation 70.5 ± 7.9 
years; 50.8% female; median body mass index 26.4 kg/
m2 (interquartile range 24.2–28.9)) of whom 74 (4.7%) 
had psoriasis. Prevalence of advanced liver fibrosis was 
8.1% in psoriasis patients compared with 3.6% in the re-
ference group (p = 0.05). The risk of advanced liver fibro-
sis in psoriasis patients remained comparable after ad-
justment for demographics, lifestyle characteristics and 
laboratory findings (odds ratio 2.57 (95% confidence in-
terval 1.00–6.63). This study suggests that elderly people 
with psoriasis are twice as likely to have advanced liver 
fibrosis irrespective of common risk factors. Key words: 
liver fibrosis; non-alcoholic fatty liver disease; psoriasis; 
comorbidity; metabolic syndrome; transient elastography.
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In psoriasis patients the prevalence of non-alcoholic 
fatty liver disease (NAFLD) is 46–59% (1, 2). NAFLD 
encompasses a wide spectrum of liver damage, ranging 
from simple fatty liver to advanced fibrosis including 
liver cirrhosis and complications, such as portal hyper-
tension and hepatocellular carcinoma.
Remarkably, no data are available on the prevalence of 
advanced liver fibrosis in patients with psoriasis. Based on 
an increased prevalence of NAFLD in patients with pso-
riasis, an increased prevalence of advanced liver fibrosis is 
expected. Furthermore it has been observed that patients 
with psoriasis are more likely to develop methotrexate 
(MTX)-induced liver toxicity compared with patients 
with rheumatoid arthritis and Crohn’s disease (3, 4). 
For our study, we used data from the Rotterdam 
Study, an on-going large prospective population-based 
cohort study in middle-aged and elderly participants. 
The specific design of the Rotterdam Study provides the 
opportunity to evaluate liver disease in all participants 
independent of their health status, using transient elasto-
graphy (TE; Fibroscan®, EchoSens, Paris, France). 
The main objective of our study is to investigate 
whether participants with psoriasis have a higher risk of 
advanced liver fibrosis, as measured by TE, compared 
with participants without psoriasis in the population-
based Rotterdam Study (5), and how this association 
is affected by known risk factors for liver fibrosis. In 
addition, we performed subgroup analyses for partici-
pants with NAFLD.
METHODS
Study population
The current study was conducted within the Rotterdam Study, 
which started in January 1990 (5). All inhabitants, aged 55 
years and older, living in Ommoord, a district in Rotterdam, the 
Netherlands, were invited to participate. The study design has 
been described previously; its main rationale is to study factors 
that determine the occurrence of chronic diseases in elderly 
people (5). TE was added to the core protocol in January 2011 
and ultrasound was included in the fifth survey of the Rotterdam 
Study (February 2009–February 2012), which constitutes the 
baseline survey for the present study. Clinical skin examinations 
for screening dermatological conditions started in September 
2010. In addition, each participant completed an extensive 
interview, fasting blood was collected, and anthropometric 
measurements were conducted. Detailed information on drug 
prescriptions were derived from automated pharmacies, in 
which most participants (98%) are registered. 
Assessment of psoriasis
Psoriasis was diagnosed either by trained physicians in der-
matology at the research centre, or by records of general 
practitioners (GP). Among participants who were seen at the 
research centre a Psoriasis Area and Severity Index (PASI) was 
conducted. Hard copy and electronic medical records of all par-
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ticipants using anti-psoriatic drugs or who had 
a diagnostic code for psoriasis were screened 
for a diagnosis of psoriasis in general practi-
tioners’ notes, medical specialist reports and 
hospital discharge letters. Participants with 
a history of possible anti-psoriatic drug use, 
but with out a diagnosis of psoriasis, were 
excluded from the analysis. A more detailed 
description of this selection process has been 
described previously (6). Participants without 
psoriasis were defined as the reference cohort. 
The date of onset of psoriasis was the date 
of first diagnosis of psoriasis in the medical 
records, first anti-psoriatic medication avail-
able in the pharmacy database, or the self-
reported date of onset, whichever came first. 
Diagnosis of liver fibrosis
Measurement of liver stiffness was performed 
using TE (Fibroscan, EchoSens) by a single, 
certified and experienced operator. The right 
lobe of the liver was assessed through the in-
tercostal space in patients lying on their back with the right arm 
in maximal abduction. The examination lasted approximately 
5–10 min. If the distance from the skin to the liver was more 
than 2.5 cm an XL-probe was used instead of the normal M-
probe. The liver stiffness measurement (LSM) was expressed in 
kilopascals (kPa). TE was considered reliable if  ≥ 10 validated 
measurements were recorded with at least 60% success rate and 
the interquartile range (IQR) was less than 30% of the median 
LSM. LSM > 9.5 kPa was used as a cut-off for the presence 
of advanced liver fibrosis and >13 kPa was used for cirrhosis. 
This cut-off level was deliberately chosen because it yields a 
high positive predictive value for the presence of advanced 
fibrosis in various liver diseases, including (N)AFLD (7, 8). 
Diagnosis of non-alcoholic fatty liver disease 
Abdominal ultrasonography was performed by certified and 
experienced technicians, using Hitachi HI VISION 900 in all 
study participants. Images were re-evaluated by a hepatologist 
(JNLS) with more than 10 years experience in ultrasonography. 
The diagnosis of fatty liver was made based on specific ultra-
sound criteria according to the protocol by Hamaguchi et al. 
(9). Participants with any of the following possible secondary 
causes of fatty liver were excluded from the NAFLD analyses: 
(i) excessive alcohol consumption; (ii) positive hepatitis B 
surface antigen (HBsAg) or anti-hepatitis C virus (anti-HCV); 
or (iii) use of oral pharmacological agents historically asso-
ciated with fatty liver (i.e. amiodarone (n = 13), corticosteroids 
(n = 28), MTX (n = 0), and tamoxifen (n = 2)). 
Co-variables (for complete version see Appendix S11)
Participants were interviewed at home using a standardized 
questionnaire to obtain data on demographics, medical history, 
comorbid conditions, smoking behaviour, alcohol intake and 
(prior) drug use. Anthropometric measurements were performed 
by well-trained nurses. Body mass index (BMI) was calculated 
as weight (kg)/height (m2). Fasting blood samples were col-
lected on the morning of ultrasound examination.
Metabolic syndrome was defined, according to Adult Treat-
ment Panel III criteria, as the presence of at least 3 of 5 traits.
Statistical analysis
The statistical significance of differences in distribution of cate-
gorical data and continuous data between participants with and 
without psoriasis was determined using χ2 tests, Student’s t-tests 
or Wilcoxon rank-sum tests. For further details see Appendix S11. 
RESULTS
Study population
TE and conclusive psoriasis data were available for 
2,466 participants of the Rotterdam Study (flowchart 
Fig. S11). From this population 1,535 participants had 
a reliable TE (62.2%), which was similar between the 
psoriasis and reference population. Participants with a 
pacemaker (1.4%), an unreliable TE (27.9%) or failure 
of the TE (9.8%) were excluded. The proportion of 
overweight and obese participants was significantly 
higher among those with failure of the TE (88.7%, 
p < 0.001) or unreliable TE (74.9% p < 0.001) compa-
red with those with a reliable TE (64.8%). Regarding 
reliability of TE, no differences were observed between 
the psoriasis and reference populations. 
Of 1,535 participants, 74 (4.8%) had psoriasis; the 
remaining 1,461 were defined as the reference popula-
tion. The distribution of age and sex was comparable 
between both groups, and the majority were Cauca-
sian. Metabolic syndrome and obesity (BMI and waist 
circumference) were not significantly different between 
the participants with psoriasis and the reference popu-
lation, although the metabolic syndrome was slightly 
more prevalent in the participants with psoriasis (Table 
I). At the time of the analyses the median disease dura-
tion of psoriasis was 11.2 years (IQR 15.8 years) and 
no participant was using systemic anti-psoriatic drugs. 
Furthermore, by then almost half of the patients with 
psoriasis had received a dermatological examination 
at the research centre, and had a median PASI score of 
Fig. 1. Distribution of reliable measurements of liver stiffness in psoriasis and reference 
participants. Transient elastography (TE) was used to measure liver stiffness (p = 0.08).
30%
20%
10%
  0%
P
ar
tic
ip
an
ts
Liver stiffness (kPa)
reference (n=1,461)
psoriasis (n=74)
<2 2.0–2.9 3.0–3.9 4.0–4.9 5.0–5.9 6.0–6.9 7.0–7.9 8.0–9.5 9.6–13 >13 
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2161
Acta Derm Venereol 96
215Increased prevalence of advanced liver fibrosis in psoriasis
2.0 (IQR 3.2), representing a population with predomi-
nately mild psoriasis.
Liver fibrosis evaluation
The risk factors for liver fibrosis were generally com-
parable between participants with and without psoriasis 
(Table I). However, the prevalence of steatosis, diag-
nosed by ultrasonography, was greater in participants 
with psoriasis vs. the reference population (44.3% vs. 
34.0%, respectively, p = 0.02) (Fig. S11). The preva-
lence of advanced fibrosis, defined as a LSM > 9.5kPa, 
was 8.1% in the psoriasis participants and 3.6% in the 
reference participants, which is an almost 2.5 times 
higher risk of advanced fibrosis for participants with 
psoriasis (crude OR 2.39; 95% CI 0.99–5.76). Distri-
bution of reliable measurements of liver stiffness in 
psoriasis and reference participants (Fig. 1). The cha-
racteristics of participants with psoriasis with advanced 
fibrosis are summarized in Table SI1.
After adjustment for age and sex, psoriasis remai-
ned associated with advanced liver fibrosis (LSM 
> 9.5kPa) (adjusted OR 2.36, 95% CI 0.95–5.85). The 
OR increased slightly to 2.57 (95% CI 1.00–6.63) after 
additional adjustment for age, sex, alcohol consump-
tion, ALT, presence of the metabolic syndrome and 
steatosis in a multivariable logistic regression model 
(Table SII1).
Linear regression analysis also showed that psoria-
sis is a predictor for the severity of fibrosis measured 
as log-LSM (crude β 0.04, standard error (SE) 0.02, 
p = 0.03). After adjusting for age, sex, alcohol consump-
tion, ALT and presence of the metabolic syndrome and 
steatosis this correlation remained the same (adjusted 
β 0.04, SE 0.02, p = 0.04). 
Non-alcoholic fatty liver disease population
A subgroup analysis was performed for participants 
with NAFLD. Of 2,502 participants, 400 were excluded 
because of the presence of secondary causes of liver 
steatosis. One-third of the remaining 2,102 participants 
had NAFLD (n = 704), and of these 39 (5.5%) had pso-
riasis. In this subgroup analysis 395 participants had 
reliable TE data (56%). The psoriasis participants were 
significantly older (74 vs. 70 years p = 0.02) than the 
Table I. General characteristics of the study population stratified by psoriasis and non-alcoholic fatty liver disease (NAFLD)
Co-variables
All participants Participants with NAFLD
Reference 
(n = 1,461; 95.3%)
Psoriasis 
(n = 74; 4.7%) pa-value
Reference 
(n = 375; 94.9%)
Psoriasis 
(n = 20; 5.1%) pa-value
Age, years, mean ± SD 70.5 ± 8.0 71.2 ± 6.5 0.34 69.6 ± 7.6 73.6 ± 6.5 0.02
Female, % 51.1 44.6 0.27 50.4 60.0 0.40
Caucasian, % 95.4 98.6 0.21 94.5 94.7 0.72
Body mass index (kg/m2), median interquartile range (IQR) 26.4 (24.2–28.9) 26.6 (24.1–28.5) 0.47 29.0 (26.9–31.2) 28.5 (26.7–32.5) 0.74
Alcohol intake (drinks/week), median (IQR) 5.0 (0.6–7.5) 7.5 (0.9–7.5) 0.07 2.63 (0.56–7.5) 4.97 (0.23–7.5) 0.75
Alcoholic more than 14  units/week, % 13.2 17.8 0.26 n/a n/a n/a
Viral hepatitis, % 0.8 1.4 0.57 n/a n/a n/a
Hepatotoxic medication, % 2.8 2.7 0.96 n/a n/a n/a
Smoking, % 0.45 0.63
Never 34.6 27.4 33.3 25.0
Former 53.9 60.3 59.7 70.0
Current 11.5 12.3 6.9 5.0
Metabolic syndrome, %b 46.5 52.1 0.36 68.5 83.3 0.18
Fasting glucose >100 mg/dl or drug treatment for elevated 
blood glucose, %
47.0 41.4 0.40 66.3 60.0 0.62
Waist circumference >88 cm (♀) or >102 cm (♂), % 34.2 45.8 0.07 61.6 81.2 0.12
Triglycerides >150 mg/dl or drug treatment for elevated 
triglycerides, %
41.7 41.1 0.93 52.5 64.3 0.39
HDL-C <40 mg/dl (♂) or <50 mg/dl (♀) or drug treatment 
for low HDL-C, %
37.3 37.5 0.97 47.4 42.9 0.74
BP ≥ 130/85 mmHg or drug treatment for elevated BP, % 91.7 88.1 0.34 96.0 93.8 0.66
Alanine aminotransferase (U/l), median (IQR) 18 (14–24) 18 (14–24) 0.89 22 (16–28) 22 (17–25) 0.94
Aspartate aminotransferase (U/l), median (IQR) 25 (22–29) 24 (21–31) 0.67 25 (22–29) 25 (21–30) 0.63
Gamma glutamyl transferase (U/l), median (IQR) 23 (17–34) 25 (19–37) 0.20 26 (19–37) 26 (21–40) 0.55
Bilirubin, median (IQR) 8 (6–11) 9 (6–12) 0.52 8.0 (6.0–11.0) 6.5 (5.8–11.0) 0.24
Platelet count (g/l), median (IQR) 258 (217–301) 271 (231–332) 0.008 255 (211–311) 271 (186–323) 0.98
HOMA-IR, median (IQR) 2.5 (1.6–3.7) 2.5 (1.8–3.7) 0.66 3.9 (2.6–5.9) 4.2 (2.9–5.4) 0.90
Steatosis on ultrasound, % 34.0 44.3 0.016 n/a n/a n/a
Cirrhosis on Fibroscan, % 1.1 3.4 0.13 1.6 8.6 0.005
Advanced liver fibrosis on Fibroscan, % 3.6 8.1 0.045 4.0 15.0 0.022
Fibroscan stiffness (kPa), median (IQR) 4.9 (4.1–6.2) 5.4 (4.4–6.6) 0.10 5.3 (4.4–6.7) 6.3 (4.9–7.3) 0.066
aSignificance level between reference population and psoriasis. Based on t-test, Wilcoxon rank-sum test or χ2 test. bMetabolic syndrome was defined as the 
presence of at least 3 of the 5 traits.
HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; HDL-C: high-density lipoprotein cholesterol; BP: blood pressure; N/A: not applicable.
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reference participants, but the distribution of the other 
co-variables, such as sex, BMI, the metabolic syndrome 
and liver enzyme tests, were comparable. Using TE, a 
significantly greater prevalence of advanced fibrosis 
was demonstrated in participants with psoriasis vs. the 
reference population (15% vs. 4%, p = 0.02). Moreover, 
more participants with psoriasis had a LSM > 13 kPa, 
suggesting liver cirrhosis, than the reference population 
(8.6% vs. 1.6%, p = 0.005) (Table I).
Logistic regression analyses in this NAFLD popula-
tion showed that participants with psoriasis had a 4 times 
greater risk of advanced liver fibrosis compared with the 
reference population (crude OR 4.2, 95% CI 1.1–16.0). 
This risk remained 4 times increased after adjustment for 
age, sex, alcohol consumption, ALT and presence of the 
metabolic syndrome in a multivariable logistic regres-
sion model (fully adjusted OR = 4.1, 95% CI 1.01–17.0).
Furthermore, in a linear regression analysis, the asso-
ciation between psoriasis and liver fibrosis (continuous 
LSM) was also confirmed (crude and fully adjusted β 
0.07, SE 0.04 p = 0.04). 
DISCUSSION
This is the first large population-based cohort study 
of middle-aged and elderly people to demonstrate that 
participants with psoriasis have a 2-fold higher risk 
of advanced liver fibrosis than participants without 
this skin disease. This risk increases up to 4 times 
among the subgroup of participants with NAFLD and 
is independent of systemic anti-psoriatic drugs and 
other known risk factors associated with liver fibrosis. 
Previous studies focused on liver fibrosis in the con-
text of MTX-induced hepatotoxicity, but were limited 
in sample size and restricted to patients with severe 
psoriasis who were eligible for liver biopsy in tertiary 
centres (12, 13). In contrast to the 8.1% of patients 
with psoriasis who had advanced liver fibrosis based on 
TE, the prevalence of advanced liver fibrosis in MTX-
treated patients ranged from 6.9% to 69.5% (13). The 
prevalence of liver fibrosis in our non-psoriatic refe-
rence population (3.6%) is similar to that observed in 
other population-based studies confirming the validity 
of the ascertainment of liver fibrosis using TE (14).
It is known that ALT is a poor diagnostic marker 
for NAFLD and liver fibrosis. Other diagnostic tests 
including TE, FibroTest, Procollagen III N-Terminal 
Propeptide, and the Enhanced Liver Fibrosis (ELF™, 
Siemens Healthcare, The Netherlands) test are more 
accurate in detecting liver fibrosis and seem more 
appropriate in monitoring drug-induced effects in the 
follow-up of patients with psoriasis, if indicated. 
In clinical practice it could therefore be considered 
appropriate to refer patients with psoriasis and an in-
creased baseline hepatic risk profile to a hepatologist 
for a TE before commencing potentially hepatotoxic 
medication. During systemic therapy TE may be repea-
ted at regular intervals, depending on the baseline TE, 
to monitor for signs of liver fibrosis. A liver biopsy may 
be considered in patients with a LSM of >9.5 kPa depen-
ding on the patients’ clinical background and is strongly 
recommended in patients with a LSM of >13 kPa (14). 
Conventional explanations for the association of 
NAFLD, advanced liver fibrosis and psoriasis are the 
increased presence of components of the metabolic 
syndrome, increased alcohol intake, and the use of hepa-
totoxic medication, but the distribution of these factors 
was comparable between the patients with psoriasis 
and the reference population. The low-grade chronic 
inflammatory state, seen both in psoriasis and NAFLD, 
may play a role in the development of advanced fibrosis, 
but this needs to be studied in more detail to determine 
whether it is the missing link in the relationship between 
these diseases (15, 16). However, inflammation does 
not explain the fact that MTX toxicity is seen more 
often in patients with psoriasis than in patients with 
rheumatic or Crohn’s disease (3, 4). Other hypotheses 
for the increased prevalence of advanced liver fibrosis 
in psoriasis are possible genetic similarities, lifestyle 
factors, such as nutrition, that were not included in the 
analyses or another still unknown common pathway for 
psoriasis and liver fibrosis.
Study strengths and limitations
The strengths of this study are its population-based de-
sign, the large number of participants, and the extensive 
availability of demographic, pharmacological, disease 
and lifestyle factors and serological markers of liver 
damage. In the adjusted models, we were able to include 
most of the known confounders that could influence the 
association of both advanced liver fibrosis and NAFLD 
with psoriasis. The study was performed in a district of 
Rotterdam that was highly representative of the Dutch el-
derly general population. Notwithstanding the large num-
ber of participants, the available cases with psoriasis and 
liver fibrosis was small, which explains the borderline 
significance often found in this study and the wider range 
of the confidence interval in the NAFLD subpopulation. 
However, the different analytic approaches and subgroup 
analysis all show the same trend suggesting the validity 
of the findings in this study population of predominantly 
mild cases without systemic anti-psoriatic medication. 
An intrinsic limitation of the cross-sectional study design 
is that a direct causal relationship between psoriasis and 
advanced liver fibrosis cannot be established. 
The case definition (i.e. psoriasis) is based on an 
algorithm, which included a clinical examination by a 
trained physician, with a high specificity and sensiti-
vity (both 98%) (6). Since the population consisted of 
elderly participants, the results may not be generalized 
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to younger subjects with psoriasis. This also explains 
the high prevalence of psoriasis compared with other 
population-based studies. 
At present, liver biopsy remains the gold standard 
for the assessment of liver fibrosis (17). However, dif-
ferent non-invasive methods have been evaluated in 
recent years, including TE (18). A recent meta-analysis 
concluded that a higher stage of liver fibrosis (a higher 
cut-off value) improves the test accuracy of TE (7). 
We used a cut-off value of 9.6 kPa (≤ F3), which is 
the highest value to detect liver fibroses next to liver 
cirrhosis (> 13 kPa; F4). Another shortcoming of our 
study is the failure rate or unreliable TE in one-third of 
the participants, which mostly affected overweight and 
obese patients irrespective of using an XL probe. This 
may have led to a selection bias and underestimation of 
the prevalence of advanced liver fibrosis in our study. 
However, the failure rate of TE was equally distributed 
amongst participants with and without psoriasis, sug-
gesting a non-differential misclassification bias. 
Conclusion
These results suggest that middle-aged and elderly pe-
ople with predominately mild psoriasis and no systemic 
anti-psoriatic medication have an increased risk of ad-
vanced liver fibrosis, independent of other known risk 
factors, especially if they have pre-existing NAFLD. 
In clinical practice this may lead to a reconsideration 
of the current role of ALT in monitoring the develop-
ment of liver fibroses, and may stimulate the use of 
other diagnostic approaches, such as TE, especially in 
psoriasis patients with (components of) the metabolic 
syndrome that are being screened prior to and during 
potentially hepatotoxic therapies.
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